Leadership Changes, Financial Results, Dividends, Stock Performance Update, and Recognitions - Research Report on Teva, Vertex,

 Leadership Changes, Financial Results, Dividends, Stock Performance Update,
   and Recognitions - Research Report on Teva, Vertex, Zoetis, Humana, and
                           Community Health Systems

PR Newswire

NEW YORK, November 4, 2013

NEW YORK, November 4, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Teva
Pharmaceutical Industries Ltd. (ADR) (NYSE: TEVA), Vertex Pharmaceuticals
Incorporated (NASDAQ: VRTX), Zoetis Inc. (NYSE: ZTS), Humana Inc. (NYSE: HUM),
and Community Health Systems Inc. (NYSE: CYH). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Teva Pharmaceutical Industries Ltd. (ADR) Research Report

On October 30, 2013, Teva Pharmaceutical Industries Ltd. (ADR) (Teva)
announced that the Company's Board of Directors has approved Dr. Jeremy
Levin's decision to step down from the role of President and CEO of the
Company. Teva added that its Board of Directors has asked Eyal Desheh, Teva's
Executive Vice President and CFO, to step in as the new President and CEO of
Teva, on an interim basis, with immediate effect, until it finds a permanent
successor for the role. Dr. Phillip Frost, Chairman of the Board, said, "On
behalf of the entire Board of Directors, I would like to thank Dr. Jeremy
Levin for his meaningful contribution to Teva during the last two years. The
Board and management team are fully committed to the implementation of Teva's
strategy, including the development of new compounds, making strategic
acquisitions, forming joint ventures and the planned acceleration of the
Company's cost reduction program." The Full Research Report on Teva
Pharmaceutical Industries Ltd. (ADR) - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/e3a3_TEVA]

Vertex Pharmaceuticals Incorporated Research Report

On October 29, 2013, Vertex Pharmaceuticals Incorporated (Vertex) reported its
Q3 2013 financial results. The Company's total revenues declined 34.0% YoY to
$221.7 million during the quarter. Net loss attributable to Vertex was $124.1
million or $0.54 per diluted share, in Q3 2013, compared to net loss
attributable to Vertex of $57.5 million or $0.27 per diluted share, in Q3
2012. Jeffrey Leiden, M.D., Ph.D., Chairman, President and CEO of Vertex,
said, "Our business is at a unique point in its evolution. We have a
tremendous opportunity ahead of us to further transform the treatment of
cystic fibrosis, which continues to be the company's highest priority
development program. Following the continued decline in the number of people
starting treatment with INCIVEK, we today took the difficult step to reduce
our workforce supporting this medicine, enabling us to focus our investment on
key programs in cystic fibrosis and other diseases to position the company for
future growth." The Full Research Report on Vertex Pharmaceuticals
Incorporated - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e696_VRTX]

Zoetis Inc. Research Report

On October 30, 2013, Zoetis Inc.'s (Zoetis) stock rose 0.09%, ending the day
at $32.06. Over the previous three trading sessions, shares of Zoetis declined
1.26% compared to the S&P 500, which gained 0.20% during the same period. The
Full Research Report on Zoetis Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/7e25_ZTS]

Humana Inc. Research Report

On October 30, 2013, Humana Inc. (Humana) announced that the Company's Board
of Directors has declared a cash dividend of $0.27 per share, which is payable
on January 31, 2014 to stockholders of record as of the close of business on
December 31, 2013. The Full Research Report on Humana Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/496b_HUM]

Community Health Systems Inc. Research Report

On October 30, 2013, Community Health Systems Inc. (Community Health)
announced that 63 of the Company's affiliated hospitals have been recognized
as Top Performers on Key Quality Measures by The Joint Commission, a leading
accrediting agency for healthcare organizations. The Company said that of the
63 Community Health's affiliate hospitals that were recognized in 2013, 25
have appeared on The Joint Commission's Top Performers list for three years.
Commenting on the news, Wayne T. Smith, Chairman, President and CEO of
Community Health, said, "This recognition underscores our organization's very
strong commitment to quality and patient safety, and demonstrates that
physicians, nurses and other caregivers in our affiliated hospitals remain
diligent in their use of evidence-based practices that can lead to better
outcomes. We applaud the efforts of the hospitals that achieved this
distinction and especially commend those that have sustained such a high level
of clinical excellence over the years." The Full Research Report on Community
Health Systems Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7587_CYH]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to making mistakes. If you notice any errors
    or omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.